Real-world comparative outcomes of US type 2 diabetes patients initiating analog basal insulin therapy

References

• Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2012;35:1364-79
   PubMed Web of Science ®Google Scholar
• Li C, Ford ES, Zhao G, et al. Trends of insulin use among US adults with type 2 diabetes: the Behavioral Risk Factor Surveillance System, 1995–2007. J Diabetes Complications 2012;26:17-22
   PubMed Web of Science ®Google Scholar
• 2007–2009 National Health Interview Survey. National Center for Health Statistics, Centers for Disease Control and Prevention. Available at: www.cdc.gov/nchs/nhis.htm [Last accessed 5 February 2013]
   Google Scholar
• Migdalis IN. Insulin analogs versus human insulin in type 2 diabetes. Diabetes Res Clin Pract 2011;93(Suppl 1):S102-4
   PubMed Web of Science ®Google Scholar
• Pontiroli AE, Miele L, Morabito A. Metabolic control and risk of hypoglycaemia during the first year of intensive insulin treatment in type 2 diabetes: systematic review and meta-analysis. Diabetes Obes Metab 2012;14:433-46
   PubMed Web of Science ®Google Scholar
• Hollander P, Cooper J, Bregnhøi J, Pedersen CB. A 52-week, multinational, open-label, parallel-group, noninferiority, treat-to-target trial comparing insulin detemir with insulin glargine in a basal-bolus regimen with mealtime insulin aspart in patients with type 2 diabetes. Clin Ther 2008;30:1976-87
   PubMed Web of Science ®Google Scholar
• Swinnen SG, Simon AC, Holleman F, et al. Insulin detemir versus insulin glargine for type 2 diabetes mellitus. Cochrane Database Syst Rev 2011 Jul 6;(7):CD006383
   PubMed Web of Science ®Google Scholar
• Annemans L, Aristides M, Kubin M. Real-life data: A growing need. ISPOR Connections 2007;13:8-12
   Google Scholar
• Kent DM, Hayward RA. Limitations of applying summary results of clinical trials to individual patients. The need for risk stratification. JAMA 2007;298:1209-12
   PubMed Web of Science ®Google Scholar
• Xie L, Wei W, Pan C, et al. A real-world study of patients with type 2 diabetes initiating basal insulins via disposable pens. Adv Ther 2011;28:1000-11
   PubMed Web of Science ®Google Scholar
• Du J, Wei W, Xie L, et al. Real-world outcomes of initiating two different basal insulin therapies via disposable pens among patients with type 2 diabetes in US employer-sponsored health plans. Value Health 2011;14:A476;PDB25
   Web of Science ®Google Scholar
• Pan C, Tangirala M, Wei W, Lin J. Health outcomes of initiating basal analog insulin via disposable pens among patients with type-2 diabetes in a national managed care plan in the United States. Value Health 2012;15:A172;PDB11
   Web of Science ®Google Scholar
• Donner T, Muñoz M. Update on insulin therapy for type 2 diabetes. J Clin Endocrinol Metab 2012;97:1405-13
   PubMed Web of Science ®Google Scholar
• Nelson SE. Detemir as a once-daily basal insulin in type 2 diabetes. Clin Pharmacol 2011;3:27-37
   Google Scholar
• Vergès B, Brun JM, Tawil C, et al. Strategies for insulin initiation: insights from the French LIGHT observational study. Diabetes Metab Res Rev 2012;28:97-105
   PubMed Web of Science ®Google Scholar
• Philis-Tsimikas A, Charpentier G, Clauson P, et al. Comparison of once-daily insulin detemir with NPH insulin added to a regimen of oral antidiabetic drugs in poorly controlled type 2 diabetes. Clin Ther 2006;28:1569-81
   PubMed Web of Science ®Google Scholar
• Leahy JL, Vlajnic A, Rimler MS. Weight gain and better efficacy outcomes in patients with type 2 diabetes starting insulin treatment with lower baseline A1C. Diabetologia 2011;54(Suppl 1):1-542
   Google Scholar
• Crawford AG, Cote C, Couto J, et al. Comparison of GE Centricity Electronic Medical Record database and National Ambulatory Medical Care Survey findings on the prevalence of major conditions in the United States. Popul Health Manag 2010;13:139-50
   PubMed Web of Science ®Google Scholar
• Charlson M, Szatrowski TP, Peterson J, Gold J. Validation of a combined comorbidity index. J Clin Epidemiol 1994;47:1245-51
   PubMed Web of Science ®Google Scholar
• Davis SN, Wei W, Garg S. Clinical impact of initiating insulin glargine therapy with disposable pen versus vial in patients with type 2 diabetes mellitus in a managed care setting. Endocr Pract 2011;17:845-52
   PubMed Web of Science ®Google Scholar
• Baser O, Wei W, Baser E, Xie L. Clinical and economic outcomes in patients with type 2 diabetes initiating insulin glargine disposable pen versus exenatide BID. J Med Econ 2011;14:673-80
   PubMedGoogle Scholar
• Levin P, Wei W, Wang L, et al. Combination therapy with insulin glargine and exenatide: real-world outcomes in patients with type 2 diabetes. Curr Med Res Opin 2012;28:439-46
   PubMed Web of Science ®Google Scholar
• Xie L, Zhou S, Wei W, et al. Does pen help? A real-world outcomes study of switching from vial to disposable pen among insulin glargine-treated patients with type 2 diabetes mellitus. Diabetes Tech Therapeut 2013;15:230-6
   PubMed Web of Science ®Google Scholar
• Zhao Y, Campbell CR, Fonseca V, Shi L. Impact of hypoglycemia associated with antihyperglycemic medications on vascular risks in veterans with type 2 diabetes. Diabetes Care 2012;35:1126-32
   PubMed Web of Science ®Google Scholar
• Rassen JA, Shelat AA, Myers J, et al. One-to-many propensity score matching in cohort studies. Pharmacoepidemiol Drug Saf 2012;21(Suppl 2):69-80
   PubMed Web of Science ®Google Scholar
• Niven DJ, Berthiaume LR, Fick GH, Laupland KB. Matched case–control studies: a review of reported statistical methodology. Clin Epidemiol 2012;4:99-110
   PubMedGoogle Scholar
• Austin PC. Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples. Stat Med 2009;28:3083-107
   PubMed Web of Science ®Google Scholar
• Asche C, LaFleur J, Conner C. A review of diabetes treatment adherence and the association with clinical and economic outcomes. Clin Ther 2011;33:74-109
   PubMed Web of Science ®Google Scholar
• Wei W, Pan P, Xie L, Baser OP. Association of treatment persistence and adherence with real-world outcomes among insulin-treated patients with type 2 diabetes mellitus (T2DM). Diabetes 2012;61(Suppl 1):A4;13-OR
   Google Scholar